Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

4D-310

Gene therapy (AAV vector) · Gene replacement · developed by 4D Molecular Therapeutics

Phase 1/2 Most advanced trial
1 Registered trials

What is 4D-310?

4D-310 is an adeno-associated virus gene therapy with a replication-incompetent capsid (4D-C102) carrying a codon-optimized full-length human GLA transgene under the CAG promoter. It is studied in Fabry disease, an inherited genetic disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Cardiovascular, Neurology
Developer
4D Molecular Therapeutics
In trials of
FDMT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
K24R94BC3K

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04519749 Phase 1/2 Fabry Disease Active not recruiting FDMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fabry Disease

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.